1887

Abstract

The aim of this study was to identify recurrent respiratory papillomatosis patients who may benefit from interferon (IFN)- treatment and to determine the means of IFN- action. The presence of human papillomavirus (HPV) and viral load and proliferation rate in pre-, ongoing and post-treatment respiratory papillomatosis biopsies were examined retrospectively in 25 patients, 18 of whom were IFN- treated and seven of whom were IFN- non-treated. Using PCR, HPV was found to be present in 20/25 respiratory papillomatosis patients and HPV type was determined for 18/25 patients (12 HPV6 and six HPV11). Eighteen of the patients were treated with IFN-, 14 of whom were HPV positive (eight HPV6, five HPV11 and one undefined HPV). Response to IFN- therapy was observed in 12 patients (7/8 HPV6, 3/5 HPV11, 1/1 undefined HPV and 1/4 HPV negative), while six patients (1/8 HPV6, 2/5 HPV11 and 3/4 HPV negative) did not respond to therapy. Viral load, determined by quantitative real-time PCR (between 0·03 and 533 HPV copies per cell), and proliferation rate, determined as the percentage of Ki-67-positive cells (between 8 and 54 %), were similar in IFN--treated and non-treated patients and were generally unaffected by IFN- treatment. In summary, most (12/18) IFN--treated patients responded to therapy. Moreover, there was a tendency for patients with HPV6-positive (7/8) respiratory papillomatosis to respond more frequently to IFN- therapy than patients with HPV11 (3/5) or HPV-negative (1/4) respiratory papillomatosis. Finally, the presence of HPV and viral load and proliferation in respiratory papillomatosis biopsies was similar in patients treated or not with IFN- and were in general unaffected by IFN- treatment.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80849-0
2005-06-01
2019-10-16
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/6/vir861695.html?itemId=/content/journal/jgv/10.1099/vir.0.80849-0&mimeType=html&fmt=ahah

References

  1. Aaltonen, L. M., Rihkanen, H. & Vaheri, A. ( 2002; ). Human papillomavirus in larynx. Laryngoscope 112, 700–707.[CrossRef]
    [Google Scholar]
  2. Abramson, A. L., Steinberg, B. M. & Winkler, B. ( 1987; ). Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Laryngoscope 97, 678–685.
    [Google Scholar]
  3. Bonagura, V. R., Vambutas, A., DeVoti, J. A., Rosenthal, D. W., Steinberg, B. M., Abramson, A. L., Shikowitz, M. J., Gjertson, D. W. & Reed, E. F. ( 2004; ). HLA alleles, IFN-γ responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum Immunol 65, 773–782.[CrossRef]
    [Google Scholar]
  4. Corbitt, G., Zarod, A. P., Arrand, J. R., Longson, M. & Farrington, W. T. ( 1988; ). Human papillomavirus (HPV) genotypes associated with laryngeal papilloma. J Clin Pathol 41, 284–288.[CrossRef]
    [Google Scholar]
  5. Dahlgren, L., Mellin, H., Wangsa, D. & 7 other authors ( 2003; ). Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 107, 244–249.[CrossRef]
    [Google Scholar]
  6. de Roda Husman, A. M., Walboomers, J. M., van den Brule, A. J., Meijer, C. J. & Snijders, P. J. ( 1995; ). The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76, 1057–1062.[CrossRef]
    [Google Scholar]
  7. Deunas, L., Alcantud, V., Alvarez, F. & 22 other authors ( 1997; ). Use of interferon-alpha in laryngeal papillomatosis: eight years of the Cuban national programme. J Laryngol Otol 111, 134–140.
    [Google Scholar]
  8. Go, C., Schwartz, M. R. & Donovan, D. T. ( 2003; ). Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. Ann Otol Rhinol Laryngol 112, 298–302.[CrossRef]
    [Google Scholar]
  9. Grander, D. & Einhorn, S. ( 1998; ). Interferon and malignant disease – how does it work and why doesn't it always? Acta Oncol 37, 331–338.[CrossRef]
    [Google Scholar]
  10. Karlsen, F., Kalantari, M., Jenkins, A., Pettersen, E., Kristensen, G., Holm, R., Johansson, B. & Hagmar, B. ( 1996; ). Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 34, 2095–2100.
    [Google Scholar]
  11. Kimberlin, D. W. ( 2004; ). Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res 63, 141–151.[CrossRef]
    [Google Scholar]
  12. Kimberlin, D. W. & Malis, D. J. ( 2000; ). Juvenile onset recurrent respiratory papillomatosis: possibilities for successful antiviral therapy. Antiviral Res 45, 83–93.[CrossRef]
    [Google Scholar]
  13. Lie, E. S., Heyden, A., Johannesen, M. K., Boysen, M. & Brandtzaeg, P. ( 1996; ). Detection of human papillomavirus in routinely processed biopsy specimens from laryngeal papillomas: evaluation of reproducibility of polymerase chain reaction and DNA in situ hybridization procedures. Acta Otolaryngol 116, 627–632.[CrossRef]
    [Google Scholar]
  14. Mellin, H., Friesland, S., Lewensohn, R., Dalianis, T. & Munck-Wikland, E. ( 2000; ). Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89, 300–304.[CrossRef]
    [Google Scholar]
  15. Mellin, H., Dahlgren, L., Munck-Wikland, E., Lindholm, J., Rabbani, H., Kalantari, M. & Dalianis, T. ( 2002; ). Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102, 152–158.[CrossRef]
    [Google Scholar]
  16. Pou, A. M., Rimell, F. L., Jordan, J. A., Shoemaker, D. L., Johnson, J. T., Barua, P., Post, J. C. & Ehrlich, G. D. ( 1995; ). Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Ann Otol Rhinol Laryngol 104, 758–762.[CrossRef]
    [Google Scholar]
  17. Rabah, R., Lancaster, W. D., Thomas, R. & Gregoire, L. ( 2001; ). Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 4, 68–72.[CrossRef]
    [Google Scholar]
  18. Sangfelt, O., Erickson, S. & Grander, D. ( 2000; ). Mechanisms of interferon-induced cell cycle arrest. Front Biosci 5, D479–D487.[CrossRef]
    [Google Scholar]
  19. Steinberg, B. M., Gallagher, T., Stoler, M. & Abramson, A. L. ( 1988; ). Persistence and expression of human papillomavirus during interferon therapy. Arch Otolaryngol Head Neck Surg 114, 27–32.[CrossRef]
    [Google Scholar]
  20. Tan, S. L. & Katze, M. G. ( 2001; ). How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284, 1–12.[CrossRef]
    [Google Scholar]
  21. Thyrell, L., Sangfeldt, O., Zhivotovsky, B., Pokrovskaja, K., Wang, Y., Einhorn, S. & Grandér, D. ( 2005; ). Human papillomavirus 16 E7 oncogene sensitizes malignant cells to interferon alpha induced apoptosis. (in press).
  22. Tieben, L. M., ter Schegget, J., Minnaar, R. P., Bouwes Bavinck, J. N., Berkhout, R. J., Vermeer, B. J., Jebbink, M. F. & Smits, H. L. ( 1993; ). Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 42, 265–279.[CrossRef]
    [Google Scholar]
  23. Yun, Z., Lewensohn-Fuchs, I., Ljungman, P., Ringholm, L., Jonsson, J. & Albert, J. ( 2003; ). A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods 110, 73–79.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80849-0
Loading
/content/journal/jgv/10.1099/vir.0.80849-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error